Duo: A Phase IIIb Individual-Level Randomized Controlled Trial of an Integrated Strategy

Starting soon · Phase 3

Conditions studied: HIV Infection, Sexually Transmitted Infection

In brief

Individual-Level Randomized Controlled Trial of an Integrated Strategy of HIV pre-exposure prophylaxis (PrEP) and sexually transmitted infection (STI) post-exposure prophylaxis (PEP) for Young Men

Key facts

Study ID

NCT07658976

Run by

HIV Prevention Trials Network

People needed

400

Starts

2026-09-01

Expected to finish

2029-09-01

Last updated by the study team

2026-06-22

Who can join

Age: 18 and older, up to 29. Sex: male. Healthy volunteers: accepted.

You may qualify if…

• Men ages 18 - 29 years
• Men who are in communities most affected by the HIV epidemic
• Willing and able to provide informed consent
• Reports having anal sex with men in the last 6 months
• Have certain risk factors for HIV acquisition, defined as any of the following in the past 6 months:
• Any condomless anal sex with a man; not including within a monogamous relationship with an HIV-negative partner or an HIV-positive partner who is virally suppressed
• Reporting 2 or more male partners, regardless of condom use
• Reporting gonorrhea, chlamydia, or syphilis diagnosis
• Any stimulant use (e.g., cocaine, amphetamines)
• Not on PrEP within the past 3 months due to participant choice
• Interested in learning more about PrEP or starting PrEP
• No evidence of HIV infection at Screening and Enrollment, based on the HIV testing algorithm
• Owns an iOS or Android mobile phone and able to successfully download mobile apps and send and receive text messages
• Must not share the mobile phone used for their participation in the study
• Able to read and write

You may not qualify if…

• Participated in HPTN 113-01
• Currently participating in another interventional trial of PrEP agents, or prior enrollment in studies of long-acting PrEP, including HPTN 083
• Plans to move away from the study area within the next year
• Currently on doxycycline for STI PEP
• Has ever used CAB-LA or other long-acting PrEP agent
• Tetracycline allergy
• Prior diagnosis of HIV infection
• Reactive HIV rapid test at Screening or reactive HIV Ag/Ab rapid test at Enrollment, regardless of subsequent HIV test results
• Any other condition that, in the opinion of the Investigator of Record (IoR)/designee, would preclude informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives would make the patient unsuitable for the study or unable/unwilling to comply with the study requirements

Where it is running

• UCLA Vine Street Clinic — Los Angeles, California, United States
• Bronx Prevention Research Center CRS — The Bronx, New York, United States
• Fundacion Huesped CRS — Buenos Aires, Argentina
• Instituto de Pesquisa Clinicaq Evandro Chagas CRS — Manguinhos, Rio de Janeiro, Brazil
• San Miguel CRS — Lima, Peru

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.